Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Medication decisions are made by licensed clinicians after intake review, and the platform does not disclose available options in advance
Microscopic evaluation revealed that vimentin treatment induced increase in adipocyte size and increase in sizes of intracellular lipid droplets with increased intracellular triglyceride
The current medications vary in mechanism and magnitude: Semaglutide (Ozempic) targets GLP-1 receptors - around 15% average weight loss Tirzepatide (Mounjaro) targets GLP-1 + GIP - around 20% weight loss, often better GI tolerance Retatrutide (Phase 3 Trials) targets three receptors around 24% weight loss in trials, with broader metabolic effects The real risk is muscle mass loss
PlexusDx provides access to prescription-strength GLP-1 therapy through licensed compounding pharmacies at a fraction of traditional pharmacy costs
